Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis

Bibliographic Details
Title: Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis
Authors: Degasperi, Elisabetta 1, Anolli, Maria Paola 1, Jachs, Mathias 2, Reiberger, Thomas 2, De Ledinghen, Victor 3, Metivier, Sophie 4, D’Offizi, Gianpiero 5, di Maria, Francesco 5, Schramm, Christoph 6, Schmidt, Hartmut 6, Zöllner, Caroline 7, Tacke, Frank 7, Dietz-Fricke, Christopher 8, Wedemeyer, Heiner 8, Papatheodoridi, Margarita 9, Papatheodoridis, George 9, Carey, Ivana 10, Agarwal, Kosh 10, Van Bömmel, Florian 11, Brunetto, Maurizia R. 12, Cardoso, Mariana 13, Verucchi, Gabriella 14, Ciancio, Alessia 15, Zoulim, Fabien 16, Aleman, Soo 17, Semmo, Nasser 18, Mangia, Alessandra 19, Hilleret, Marie-Noelle 20, Merle, Uta 21, Santantonio, Teresa A. 22, Coppola, Nicola 23, Pellicelli, Adriano 24, Roche, Bruno 25, Causse, Xavier 26, D’Alteroche, Louis 27, Dumortier, Jérome 28, Ganne, Nathalie 29, Heluwaert, Frederic 30, Ollivier, Isabelle 31, Roulot, Dominique 32, Viganò, Mauro 33, Loglio, Alessandro 34, Federico, Alessandro 35, Pileri, Francesca 36, Maracci, Monia 37, Tonnini, Matteo 38, Arpurt, Jean-Pierre 39, Barange, Karl 40, Billaud, Eric 41, Pol, Stanislas 42, Gervais, Anne 43, Minello, Anne 44, Rosa, Isabelle 45, Puoti, Massimo 46, Lampertico, Pietro 1, 47, 48, ⁎
Source: In Journal of Hepatology December 2024
Database: ScienceDirect
More Details
ISSN:01688278
DOI:10.1016/j.jhep.2024.12.044
Published in:Journal of Hepatology
Language:English